9 studies were found.

1.		No longer recruiting	Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy Conditions: stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; inflammatory breast cancer
2.		No longer recruiting	Chemotherapy in Treating Women With Resected Breast Cancer Following Tamoxifen Therapy Conditions: stage I breast cancer; stage II breast cancer; stage IIIA breast cancer
3.		No longer recruiting	Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer Conditions: stage III breast cancer; stage I breast cancer; stage II breast cancer
4.		No longer recruiting	Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer Conditions: stage IV breast cancer; recurrent breast cancer
5.		No longer recruiting	Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy Conditions: stage IV breast cancer; recurrent breast cancer
6.		No longer recruiting	Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Conditions: menopausal symptoms; stage I breast cancer; stage II breast cancer; breast cancer in situ
7.		Completed	ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer Conditions: stage I breast cancer; stage II breast cancer
8.		No longer recruiting	R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy Conditions: stage IV breast cancer; recurrent breast cancer
9.		Recruiting	Trastuzumab in Treating Women With Breast Cancer Conditions: stage I breast cancer; stage II breast cancer; stage IIIA breast cancer